Exercise Induced Asthma, House Dust Mite Allergy
Conditions
Keywords
Exercise Induced Asthma, eNO, exercise challenge, micro RNAs
Brief summary
The purpose of this study is to investigate the micro ribonucleic acid (mRNA) profiles of patients with EIA without allergic sensitization and EIA with house dust mite sensitization compared to that of healthy controls.
Detailed description
Patients with known EIA are periodically reexamined by medical history, clinical examination, bodyplethysmography, spirometry, exhaled nitric oxide (eNO), skin prick test, methacholin challenge test and exercise-challenge in a cold-chamber at 2-4°C (ECC). Additionally the investigators gathers the questionnaires: Asthma Control Test (ACT) and Dyspnoe Index (DI). Besides these standard procedures the investigators want to investigate the micro-RNA profiles in two EIA subgroups: EIA with house-dust allergy (n = 24) and EIA without house-dust allergy (n = 24). Both groups are characterized by different eNO levels. The patients with EIA and house-dust allergy should have an eNO \> 30 ppb, the patients with EIA without house-dust allergy an eNO \< 20 ppb. The micro-RNA profiles of the both EIA subgroups will be compared the micro RNA profiles of 20 healthy controls . Therefore blood will be taken (for a complete blood count and micro RNA analysis) at three points of time: before ECC, directly after ECC and after 24 hours ± 4 hours after ECC.
Interventions
DIAGNOSTIC_TESTExercise challenge in the cold chamber (ECC)
Exercise challenge (defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber. Gradient: 10%, temperature 2-4°C. After the exercise challenge controlling bodyplethysmography and spirometry after 5, 10, 15 and 30 minutes. A positive reaction is a decrease of ≥ 10% of FEV1 in comparison to the initial value.
DIAGNOSTIC_TESTmRNA profile
Blood taking with full blood exam and PAXgene tube for investigation oft the micro RNA profiles. The PAXgene Blood RNA kit insulates total RNA inclusive miRNA and small RNA which are centrifugated, pelletised, washed and incubated to detach proteins. For mapping the particular miRNA there will be generated libraries with specifical codes to match the analysis to the original probe. Next generation sequencing will be performed by MISeq REagent Kit v3 and the analysis oft the different expressions in the R Version 3.2.3. The divergent expressions will be refurbished by computer and databased.
DIAGNOSTIC_TESTstandard diagnostic
bodyplethysmography, spirometry, exhaled NO, skin prick test, asthma control test (ACT)
Sponsors
Johann Wolfgang Goethe University Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
The micro RNA profile of patients with known EIA and house dust mite allergy and patients with EIA without allergic sensitization are compared to the micro RNA profile of healthy controls
Eligibility
Sex/Gender
ALL
Age
12 Years to 24 Years
Healthy volunteers
Yes
Inclusion criteria
For EIA patients Inclusion Criteria: * written agreement * age \>=12 and \<= 24 * known exercise induced asthma * Group 1: skin prick test positiv house-dust allergy, eNO \> 30 ppb, MCT PD20 \< 0,1 mg * Group 2: skin prick test negative house-dust allergy, eNO \< 20 ppb, MCT PD20 \< 1 mg * lung function before ECC forced vital capacity (FVC) ≥ 75% and forced exspiratory pressure in one second (FEV1) ≥ 70%
Exclusion criteria
* age \< 12 und \> 24 years * lung function FVC \< 75% und FEV1\< 70% * inability to understand the range of the study * chronic asthma with systemic cortisone therapy * regular therapy with inhalative corticosteroids or leukotriene-antagonists \<14 days before visit 1 * intake of long acting beta-agonists (LABA) 48 h before examination * intake of short acting beta-agonists (SABA) 8 h before examination * acute severe infection (pneumonia) within the last 4 weeks * other chronic diseases or infections (HIV, Tbc) * pregnancy For healthy controls Inclusion Criteria: * written agreement * age \>=18 and \<= 24
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dysregulation of miRNA-146 | 1 Year | The primary endpoint is the dysregulation of miRNA-146 in comparison to the control group and within the subgroups which play an determined role in the bronchial inflammation. Therefore the total RNA, including miRNA, will be isolated using the PAXgene Blood miRNA Kit (Qiagen, Hilden, Germany). Concentration of RNA will be assessed using Nanodrop Lite spectrometry (Thermo Scientific, Dreieich, Germany). MiRNA libraries are generated with the QIAseq miRNA Library Kit (Qiagen, Hilden, Germany). Next generation sequencing (NGS) will be performed with the MiSeq Reagent Kit v3, the PhiX Sequencing Control v3 and the MiSeq™ Desktop Sequencer (all Illumina Inc., San Diego, CA, USA). Differential expression analysis will be performed in RStudio 1.2.1335 (https://cran.r-project.org/). False discovery rate correction will be applied and miRNAs are considered to be differentially expressed with p \< 0.05. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cange of eNO | 1 Year | Change of eNO after ECC in the EIA subgroups compared to the healthy controls |
| Change of leucocytes and neutrophile granulocytes | 1 Year | Change of leucocytes and neutrophile granulocytes after ECC in the EIA subgroups compared to the healthy controls |
| FEV1-decrease in ECC | 1 Year | Comparison of the FEV1-decrease in ECC with significant dysregulated miRNA in the EIA subgroups compared to the healthy controls |
| Dysregulation miRNAs affecting Th2 mediated bronchial inflammation (miRNA-126, miRNA-21, miRNA-145, let7-mimic) | 1 Year | Dysregulation of other miRNAs affecting the Th2 mediated bronchial inflammation (miRNA-126, miRNA-21, miRNA-145, let7-mimic) and compare to the control group. MiRNA preparation and measurement processes are described in Outcome 1. |
| Comparison of change of leucocytes and neutrophile granulocytes with significant dysregulated miRNA | 1 Year | Comparison of the increase of leucocytes and neutrophile granulocytes after ECC significant dysregulated miRNA in the EIA subgroups compared to the healthy controls |
| Comparison of ACT with significant dysregulated miRNA | 1 Year | Comparison of the score in ACT with significant dysregulated miRNA in the EIA subgroups compared to the healthy controls |
| Comparison of DI with significant dysregulated miRNA | 1 Year | Comparison of the scoresin DI with significant dysregulated miRNA in the EIA subgroups compared to the healthy controls |
| Comparison eNO with significant dysregulated miRNA | 1 Year | Comparison of the initial value of exhaled NO with significant dysregulated miRNA in the EIA subgroups compared to the healthy controls |
Countries
Germany
Contacts
Primary ContactMelanie Dreßler, MD
Backup ContactHelena Donath, MD
Outcome results
None listed